Gene therapy for XXXX .

@entity1 @entity1313 @entity5 @entity11 @entity463
@entity463 ( @entity463 ) is the most frequent and devastating primary @entity1313 in adults. Despite current treatment modalities, such as surgical resection followed by chemotherapy and radiotherapy, only modest improvements in median survival have been achieved. Frequent recurrence and invasiveness of @entity463 are likely due to the resistance of @entity11 stem cells to conventional treatments; therefore, novel alternative treatment strategies are desperately needed. Recent advancements in molecular biology and gene technology have provided attractive novel treatment possibilities for @entity1 with @entity463 . Gene therapy is defined as a technology that aims to modify the genetic complement of cells to obtain therapeutic benefit. To date, gene therapy for the treatment of @entity463 has demonstrated anti- @entity5 efficacy in pre-clinical studies and promising safety profiles in clinical studies. However, while this approach is obviously promising, concerns still exist regarding issues associated with transduction efficiency, viral delivery, the pathologic response of the brain, and treatment efficacy. @entity5 development and progression involve alterations in a wide spectrum of genes, therefore a variety of gene therapy approaches for @entity463 have been proposed. Improved viral vectors are being evaluated, and the potential use of gene therapy alone or in synergy with other treatments against @entity463 are being studied. In this review, we will discuss the most commonly studied gene therapy approaches for the treatment of @entity463 in preclinical and clinical studies including: prodrug/suicide gene therapy; oncolytic gene therapy; cytokine mediated gene therapy; and @entity5 suppressor gene therapy. In addition, we review the principles and mechanisms of current gene therapy strategies as well as advantages and disadvantages of each.
